Streetbeat News

Price Targets

MRNA

Over the past 3 months, 5 Wall Street analysts have provided ratings for Moderna (NASDAQ:MRNA) stock, with an average price target of $129.4, representing an implied upside from the current price of $78.73. The current average price target reflects a 25.85% decrease from the previous target of $174.50. Ratings are based on information from company calls, financial statements, and insider conversations. Analysts' opinions can vary, with 2 bullish, 1 somewhat bullish, and 2 indifferent ratings recently.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 12:00 pm

CABA

Cabaletta Bio (NASDAQ:CABA) has received positive analyst ratings in the last quarter, with 9 bullish and 4 somewhat bullish ratings, and no negative ratings. The average 12-month price target for CABA is $30.78, which is a 41.52% increase from the previous target of $21.75. The high target is $50.00 and the low target is $17.00. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial performance and company risk.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 12:00 pm

SFIX

Over the last quarter, Stitch Fix (NASDAQ:SFIX) received predominantly indifferent analyst ratings, with 9 indifferent and 1 somewhat bearish out of 10 total ratings. The average 12-month price target for SFIX is $3.73, a decrease of 15.03% from the previous target of $4.39. The high target is $5.00 and the low target is $2.50. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 12:00 pm

RLYB

Rallybio (NASDAQ:RLYB) has received 5 analyst ratings in the last quarter, with 3 bullish, 2 somewhat bullish, and none bearish. The average 12-month price target among these analysts is $16.4, with a high of $18.00 and a low of $14.00. This target is a 3.53% decrease from the previous target of $17.00. Analyst ratings are opinions on stock performance and are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 12:00 pm

CG

Analysts have provided ratings for Carlyle Group (NASDAQ:CG) with 1 bullish, 3 somewhat bullish, 2 indifferent, and no bearish ratings in the last quarter. The average price target is $40.0, representing an upside from the current price of $34.26. This target has decreased by 3.85% from the previous target of $41.60. Analyst ratings are opinions based on financial analysis and are not guarantees of performance.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 12:00 pm

CRWD

Rosenblatt analyst Catharine Trebnick has reaffirmed a Buy rating on CrowdStrike Holdings (NASDAQ:CRWD) and increased the price target from $200 to $245.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:59 am

LII

Keybanc analyst Jeffrey Hammond has maintained an Overweight rating on Lennox Intl (NYSE:LII) and increased the price target from $415 to $460.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:56 am

SWTX

HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and increased the price target from $64 to $73.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:50 am

RLYB

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Rallybio (NASDAQ:RLYB) and maintained a $17 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:48 am

WDAY

Barclays analyst Raimo Lenschow has maintained an Overweight rating on Workday (NASDAQ:WDAY) and increased the price target from $249 to $274, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:44 am